Sidley represented AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, in the expansion of the scope and breadth of its strategic collaboration with Eli Lilly and Company (“Lilly”) to research and develop innovative treatments for various cancers.
Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.
AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables the company to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials.
“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers. It is especially pleasing to continue and expand our existing relationship.”
The Sidley team was led by Alison M. Lehner (Technology and Life Sciences Transactions) and included Longbo Wang and Cassidy A. Pomeroy-Carter (also Technology and Life Sciences Transactions), Jack W. Pirozzolo (Regulatory Litigation), Matthew D. Stoker (M&A), Colleen Theresa Brown (Privacy and Cybersecurity), and Rachel D. Kleinberg and Jonathan M. Westreich (Tax).
For additional information, please see the press release.
